PHILADELPHIA, April 2, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, is pleased to announce that its most recently completed clinical trial was selected for presentation at the 72nd Scientific Sessions of the American Diabetes Association (ADA) which will be held June 8-12, 2012 in Philadelphia, PA. The study will be presented in an oral presentation that is currently scheduled on Friday, June 8 at 5:45 PM ET. The presentation entitled "Transdermal Continuous Glucose Monitoring Following Skin Permeation," by Wayne Menzie, Echo's Director of Technology and Clinical Development, will provide an expanded analysis of data collected from subjects with either type 1 or type 2 diabetes during Echo's recent clinical trial of its Symphony tCGM System. Additionally, Echo Therapeutics expects to release preliminary results from its Symphony tCGM studies in critical care patients in the next month. "We are excited to share these results on the opening day of ADA, the largest gathering of healthcare professionals in the fight against diabetes. We value this opportunity for engagement with experts in the field of diabetes research, care and services," stated Patrick Mooney, M.D., Echo's Chairman and CEO. "We believe the results of the diabetes clinical study combined with supporting data in our current critical care studies will further highlight the positive impact Symphony may have for diabetes and critical care patients." About Diabetes More than 25 million children and adults in the U.S., or over 8 percent of the population, have diabetes, according to the 2011 National Diabetes Fact Sheet. The Centers for Disease Control and Prevention predicts that nearly 30 percent of children born after the year 2000 will develop diabetes. Worldwide, the number of adults with diabetes has doubled over the last three decades to nearly 350 million and increased nearly three-fold in the U.S., according to a study published in the British journal Lancet. The total cost of diagnosed diabetes in the U.S. was estimated at $174 billion in 2007. About Echo Therapeutics Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.